0001811623
false
0001811623
2023-08-16
2023-08-16
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
August 16, 2023
PaxMedica, Inc.
(Exact name of registrant as specified in its
charter)
Delaware |
001-41475 |
85-0870387 |
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
303 South Broadway, Suite 125
Tarrytown, NY |
10591 |
(Address of principal executive offices) |
(Zip Code) |
(914) 987-2876
(Registrant’s telephone number, including
area code)
n/a
(Former name or former address, if changed since
last report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2.
below):
¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Exchange Act:
Title of each class |
|
Trading
Symbol(s) |
|
Name of each exchange
on which registered |
Common Stock, par value $0.0001 per share |
|
PXMD |
|
The Nasdaq Capital Market |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company x
If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act.
| Item 5.02 | Departure of Directors or Certain Officers; Election of
Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
Director Resignation
On August 16, 2023, Michael Derby resigned
from the Board of Directors of PaxMedica, Inc. (the “Company”) effective August 21, 2023.
On such effective
date, Howard J. Weisman, the Company’s Chief Executive Officer, will also be appointed Chairman of the Board, and current
director Charles Casamento will be appointed as Lead Independent Director.
Executive Officer Changes
On August 16, 2023, and in each case
effective August 21, 2023:
| · | Mr. Derby also resigned
from his executive position as Executive Chairman of the Board of the Company. |
| · | Zachary Rome resigned
from his position as Chief Operating Officer of the Company, but will remain on the Board
of Directors of the Company. |
| · | Stephen D. Sheldon,
the Company’s current Chief Financial Officer, was also appointed as Chief Operating
Officer of the Company |
On August 16, 2023, the Company issued a
press release with respect to the foregoing and other matters. A copy of the press release is filed herewith as Exhibit 99.1 to this
Current Report on Form 8-K.
| Item 9.01. | Financial Statements and Exhibits. |
(d) Exhibits
– The following exhibits are filed as part of this report:
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
PaxMedica, Inc. |
|
|
|
|
|
|
|
By: |
/s/ Howard
J. Weisman |
|
Name: |
Howard J. Weisman |
|
Title: |
Chief Executive Officer |
Date: August 16, 2023
Exhibit 99.1
PaxMedica Appoints David Hough M.D. as Chief
Medical Officer
Announces Additional Management Changes; Independent
Directors Now Majority of Board
TARRYTOWN, NY, August 16, 2023
-- PaxMedica, Inc. (Nasdaq: PXMD), a clinical stage biopharmaceutical company focusing on the development of novel
anti-purinergic drug therapies (APT) for the treatment of Autism Spectrum Disorder (ASD) and other serious conditions with
intractable neurologic symptoms, today announced the return of David Hough, M.D., as Chief Medical Officer (CMO) of PaxMedica,
effective immediately. Dr. Hough has been a key consultant to the company during 2023 and was the company’s CMO from
2020-2022. He is board-certified in both adult and geriatric psychiatry. He succeeds Stefan Schwabe M.D., PhD, who will continue to
serve on the PaxMedica Scientific Advisory Board.
PaxMedica also announced additional changes to
the management team and Board of Directors, all effective as of August 21, 2023. Michael Derby and Zachary Rome, Chairman of the Board
and Chief Operating Officer, respectively, and co-founders of the company in 2018, will be relinquishing their operational roles on the
management team in order to focus on their full-time responsibilities at Tardimed Sciences. Mr. Rome will remain on the Board of
Directors. Mr. Derby will remain as a consultant to PaxMedica.
Howard Weisman, Chief Executive Officer of PaxMedica,
has been appointed to the additional position of Chairman of the Board of Directors. Stephen Sheldon has been appointed to the role of
Chief Operating Officer in addition to his position as Chief Financial Officer. Charles Casamento has been elected as Lead Independent Director
of the Board of Directors.
Lead Independent Director, Charles Casamento said,
“We are grateful for the vision and leadership that Michael and Zach have shown since the inception of PaxMedica. Their determination
and strategic approach in the formation of PaxMedica and the advancement of PAX-101 (IV suramin) towards its goal of becoming the first
drug to treat the core symptoms of autism formed the bedrock of the company’s growth plans. We look forward to their future contributions
to our success.”
“We are excited to have Dr. Hough rejoin
us at this all important juncture. His extensive experience in drug development and neurological conditions has been a tremendous asset
for us, as we advance our portfolio of product candidates for the treatment of intractable neurologic symptoms, and we look forward to
his continued, significant contributions. We are delighted to welcome him back to PaxMedica as Chief Medical Officer,” added Howard
Weisman, PaxMedica’s Chairman and CEO.
Mr. Weisman continued, “I would also
like to thank Dr. Schwabe for his contribution to PaxMedica over this past critical year as a newly public company. He has been instrumental
in focusing our efforts as we work to develop innovative treatments to meet unmet needs in neurodevelopmental
disorders and will remain a valued advisor to PaxMedica.”
Dr. Hough is a neuroscience clinical development
consultant who previously served as Vice President at Janssen Research and Development (a Johnson & Johnson company) and in various
leadership roles over a 17-year span. Most recently, Dr. Hough was the compound development team leader for SPRAVATO®
for treatment-resistant depression, overseeing the development program through two severe mood disorders indications. He was responsible
for medical, scientific, manufacturing, quality, preclinical, and commercial aspects of the program. Prior to that he was the schizophrenia
disease area leader and the development team leader for paliperidone. Dr. Hough played a pivotal role in the development programs
for oral INVEGA®, INVEGA SUSTENNA®
and XEPLION® for schizophrenia. Dr. Hough is a graduate of West
Point and board certified in psychiatry.
About PaxMedica
PaxMedica is a clinical stage biopharmaceutical
company focusing on the development of anti-purinergic drug therapies (“APT”) for the treatment of disorders with intractable
neurologic symptoms, ranging from neurodevelopmental disorders, including Autism Spectrum Disorder (“ASD”), to Myalgic Encephalomyelitis/Chronic
Fatigue Syndrome (“ME/CFS”), a debilitating physical and cognitive disorder. One of PaxMedica’s primary points of focus
is the development and testing of its lead program, PAX-101, an intravenous formulation of suramin, in the treatment of ASD and the advancing
the clinical understanding of using that agent against other disorders such as ME/CFS. For more information, visit www.paxmedica.com.
Forward-Looking Statements
This press release contains “forward-looking
statements.” Forward-looking statements reflect our current view about future events. Investors can identify these forward-looking
statements by words or phrases such as “may,” “will,” “could,” “expect,” “anticipate,”
“aim,” “estimate,” “intend,” “plan,” “believe,” “is/are likely to,”
“propose,” “potential,” “continue” or similar expressions. These forward-looking statements include
our anticipated clinical program, the timing and success of our anticipated data announcements, pre-clinical and clinical trials and regulatory
filings, statements about the strength of our balance sheet. These forward-looking statements involve known and unknown risks and uncertainties
and are based on the Company’s current expectations and projections about future events that the Company believes may affect its
financial condition, results of operations, business strategy and financial needs. Such risks and uncertainties include, but are not limited
to, risks associated with the Company’s development work, including any delays or changes to the timing, cost and success of the
Company’s product development and clinical trials, risk of insufficient capital resources, cash funding and cash burn and risks
associated with intellectual property and infringement claims. The Company undertakes no obligation to update or revise publicly any forward-looking
statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law.
Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you
that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from
the anticipated results and encourages investors to review other factors that may affect its future results described in the Company’s
“Risk Factors” section and other sections in its most recent Annual Report on Form 10-K, and subsequent quarterly and
other filings with the U.S. Securities and Exchange Commission.
Contacts
ir@paxmedica.com
Stephanie Prince
PCG Advisory
sprince@pcgadvisory.com
(646) 863-6341
v3.23.2
Cover
|
Aug. 16, 2023 |
Cover [Abstract] |
|
Document Type |
8-K
|
Amendment Flag |
false
|
Document Period End Date |
Aug. 16, 2023
|
Entity File Number |
001-41475
|
Entity Registrant Name |
PaxMedica, Inc.
|
Entity Central Index Key |
0001811623
|
Entity Tax Identification Number |
85-0870387
|
Entity Incorporation, State or Country Code |
DE
|
Entity Address, Address Line One |
303 South Broadway
|
Entity Address, Address Line Two |
Suite 125
|
Entity Address, City or Town |
Tarrytown
|
Entity Address, State or Province |
NY
|
Entity Address, Postal Zip Code |
10591
|
City Area Code |
914
|
Local Phone Number |
987-2876
|
Written Communications |
false
|
Soliciting Material |
false
|
Pre-commencement Tender Offer |
false
|
Pre-commencement Issuer Tender Offer |
false
|
Title of 12(b) Security |
Common Stock, par value $0.0001 per share
|
Trading Symbol |
PXMD
|
Security Exchange Name |
NASDAQ
|
Entity Emerging Growth Company |
true
|
Elected Not To Use the Extended Transition Period |
false
|
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 2 such as Street or Suite number
+ References
+ Details
Name: |
dei_EntityAddressAddressLine2 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Section 14a -Number 240 -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
PaxMedica (NASDAQ:PXMD)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
PaxMedica (NASDAQ:PXMD)
Gráfica de Acción Histórica
De May 2023 a May 2024